Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.